Northland Capital Partners Limited Morning Report: Skinbiotherapeutics PLC

Human study design and manufacturing scale-up for cosmetic application

NORTHLAND VIEW

  • Human study: SkinBio provided the finalised design of its human study, which aims to test the efficacy of the cosmetic application of Skinbiotix®, the company’s proprietary probiotic platform.
  • The study is planned to commence in Q3’18 and is expected to last eight weeks. The trial will be conducted by Alba Science an independent clinical research organisation (CRO) based in Edinburgh.
  • The study aims to recruit 120 female volunteers presenting with self-assessed ‘dry-skin’. The volunteers will apply the cream formulation of SkinBiotix® three times a day with measurements taken regarding skin hydration, barrier-function and dryness. Skin samples will be taken at the beginning and end of the study to assess the effect of the technology on the skin microbiome.
  • Manufacture: SkinBio has trialed a new method of scale-up with no detrimental impact on the activity of the SkinBiotix® platform. Further optimisation is required to meet the required commercial levels.
  • Patents: The Company’s first patent (covering the use of bacteria and lysates in the treatment of skin in health and disease) which was granted in Australia in 2017, has been granted in New Zealand and Russia. Active prosecution is progressing in Europe, USA and China.

This announcement shows the Company is successfully continuing the progression of its cosmetic application. The cream formulation of SkinBiotix® recently passed effectiveness tests (RNS: April 17th ‘18) and is undergoing stability testing prior to use in the study. The study is expected to show that the SkinBiotix® cream will improve skin-hydration, strengthen barrier function and be safe for the skin microbiome. These are all characteristics of interest to partners for the development and commercialisation of a successful cosmetic product.

The Company has doubled the planned study sample size (originally 60 volunteers), which the Directors believe has marginal cost impact. The increase in sample size will strengthen the study data and if the trial is successful it will provide further impact in future partnering discussions.

COMPANY DESCRIPTION

SkinBio Therapeutics is a preclinical healthcare company focusing on skin health.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc involved in new research grant

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today its collaboration as industrial partner in a grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester. The

    SkinBiotherapeutics Plc

    Skinbiotherapeutics files new patent application

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today a new patent filing. The patent application is to cover the use of SkinBiotix® for increasing filaggrin levels in skin. Filaggrin is a protein

    SkinBiotherapeutics Plc

    Are Bacteria a Secret Weapon Against Eczema?

    NIH study suggests a potentially cheap and effective treatment for a painful condition. Inflammation, itching, painful skin lesions: This is everyday life for patients with atopic dermatitis, a type of eczema that affects roughly 11 percent of adults

    SkinBiotherapeutics Plc

    Skinbiotherapeutics PLC Plans for Human Study

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, has today provided the following update: Human study The design of the human study planned for Q3 2018 has now been finalised. This will be conducted

    SkinBiotherapeutics Plc

    Gateway to the Mind

    The microbiome is the strange invisible world of our non human selves. On and in all of us are hoards of microbes. Their impact on our physical health is becoming clear to science, but a controversial

    SkinBiotherapeutics Plc

    INTERVIEW: SkinBiotherapeutics Skinbiotix Positive Results in Cream

    SkinBioTherapeutics Plc (LON:SBTX) CEO Dr. Cath O’Neill talks to DirectorsTalk about the positive results skinbiotix shows in cream formulation. Cath explains the results, the significance, how the technology works, stability testing, the next major milestones and

    SkinBiotherapeutics Plc

    Pro- and prebiotics on the skin?

    An interview with Cath O’Neill by Kristin Neumann, MyMicrobiome Cath is coming from the skin research area, being an expert on skin health. During the last years her research focussed on the skins microbiome. With her company